소화기 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Gastrointestinal Therapeutics Market size is expected to reach USD 65.15 Billion in 2034 from USD 46.85 Billion (2025) growing at a CAGR of 3.73% during 2026-2034.

The global gastrointestinal therapeutics market is growing significantly due to the rising prevalence of digestive disorders worldwide. Conditions such as irritable bowel syndrome, inflammatory bowel disease, and gastroesophageal reflux disease are becoming increasingly common, driving demand for effective treatment options. Changing dietary habits, sedentary lifestyles, and increasing stress levels are major factors contributing to the growing incidence of gastrointestinal disorders. As a result, healthcare providers are focusing on improving treatment outcomes and patient care.

Pharmaceutical advancements and the development of innovative therapies are playing a crucial role in market growth. Biologics, targeted therapies, and novel drug formulations are improving the effectiveness of gastrointestinal treatments. Additionally, increased research and development activities by pharmaceutical companies are leading to the introduction of new and improved medications. The expansion of healthcare infrastructure and growing awareness about digestive health are also supporting market expansion.

In the coming years, the gastrointestinal therapeutics market is expected to witness continued growth driven by ongoing medical research and increasing healthcare investments. The rising focus on personalized medicine and targeted therapies will further enhance treatment outcomes. Moreover, the growing aging population, which is more susceptible to gastrointestinal disorders, will continue to support demand for advanced therapeutics.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Branded
• Generics

By Drug Class

• Aminosalicylates
• Digestive enzymes
• Proton Pump Inhibitors
• Laxatives
• Anti-Emetics
• H2 Antagonists
• Anti-Diarrheal
• Biologics/Biosimilar
• Others

By Route of Administration

• Oral
• Injectable
• Others

By Application

• Crohn's disease
• Ulcerative colitis
• GERD
• IBS
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AbbVie Inc, AstraZeneca, Janssen Pharmaceuticals NV, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals, Pfizer Inc, Bayer AG, Abbott, Cipla Inc, Gilead Sciences Inc, Biogen, Organon Group
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Aminosalicylates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Digestive enzymes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Proton Pump Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Laxatives Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Anti-Emetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. H2 Antagonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Anti-Diarrheal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Biologics/Biosimilar Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Application
• 7.2. Crohn's disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Ulcerative colitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. GERD Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. IBS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Type
  • 9.2.2 By Drug Class
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Application
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Type
  • 9.3.2 By Drug Class
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Application
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Type
  • 9.4.2 By Drug Class
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Application
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Type
  • 9.5.2 By Drug Class
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Application
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Type
  • 9.6.2 By Drug Class
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Application
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL GASTROINTESTINAL THERAPEUTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 AbbVie Inc
  • 11.2.2 AstraZeneca
  • 11.2.3 Janssen Pharmaceuticals NV
  • 11.2.4 Sun Pharmaceutical Industries Ltd
  • 11.2.5 Takeda Pharmaceutical Company Limited
  • 11.2.6 Salix Pharmaceuticals
  • 11.2.7 Pfizer Inc
  • 11.2.8 Bayer AG
  • 11.2.9 Abbott
  • 11.2.10 Cipla Inc
  • 11.2.11 Gilead Sciences Inc
  • 11.2.12 Biogen
  • 11.2.13 Organon Group